Ryuichi Morishita
Department of Clinical Gene Therapy
Graduate School of Medicine
Osaka University
2-2 Yamada-oka
Japan
Name/email consistency: high
- Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Azuma, J., Sawa, Y., Kaneda, Y., Ogihara, T., Morishita, R. Arterioscler. Thromb. Vasc. Biol. (2012)
- Hepatocyte Growth Factor Inhibits Lipopolysaccharide-Induced Oxidative Stress via Epithelial Growth Factor Receptor Degradation. Shimizu, K., Taniyama, Y., Sanada, F., Azuma, J., Iwabayashi, M., Iekushi, K., Rakugi, H., Morishita, R. Arterioscler. Thromb. Vasc. Biol. (2012)
- Development of nucleic Acid drugs for neurological disorders. Shimamura, M., Sato, N., Nakagami, H., Taniyama, Y., Morishita, R. Curr. Top. Med. Chem (2012)
- Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy. Osako, M.K., Nakagami, H., Morishita, R. Curr. Top. Med. Chem (2012)
- Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Okayama, K., Azuma, J., Dosaka, N., Iekushi, K., Sanada, F., Kusunoki, H., Iwabayashi, M., Rakugi, H., Taniyama, Y., Morishita, R. Hypertension (2012)
- Role of central nervous system periostin in cerebral ischemia. Shimamura, M., Taniyama, Y., Katsuragi, N., Koibuchi, N., Kyutoku, M., Sato, N., Allahtavakoli, M., Wakayama, K., Nakagami, H., Morishita, R. Stroke (2012)
- Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study. Morishit, R., Itakuraa, H., Nakaya, N., Yoshida, M., Odawara, M., Ichihara, A., Mizuno, K. Curr. Vasc. Pharmacol (2011)
- Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Morishita, R., Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Azuma, J., Taniyama, Y., Sawa, Y., Kaneda, Y., Ogihara, T. Arterioscler. Thromb. Vasc. Biol. (2011)
- Does gene therapy become pharmacotherapy?. Morishita, R., Aoki, M., Ogihara, T. Exp. Physiol. (2005)
- Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Shimamura, M., Sato, N., Oshima, K., Aoki, M., Kurinami, H., Waguri, S., Uchiyama, Y., Ogihara, T., Kaneda, Y., Morishita, R. Circulation (2004)
- Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Morishita, R., Tomita, N., Kaneda, Y., Ogihara, T. Curr. Opin. Pharmacol (2004)
- Perspective in progress of cardiovascular gene therapy. Morishita, R. J. Pharmacol. Sci. (2004)
- Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Morishita, R., Aoki, M., Hashiya, N., Makino, H., Yamasaki, K., Azuma, J., Sawa, Y., Matsuda, H., Kaneda, Y., Ogihara, T. Hypertension (2004)
- Transcription factor as molecular targets: is transcription factor decoy a novel drug?. Morishita, R. Curr. Drug. Targets (2003)
- Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease. Morishita, R., Kaneda, Y., Ogihara, T. BioDrugs (2003)